Skip to content

A study on the therapeutic efficacy of liposomal bupivacaine-guided paravertebral/intraspinal plane nerve blockade for the treatment of acute herpes zoster neuralgia and prevention of postherpetic neuralgia.

A study on the therapeutic efficacy of liposomal bupivacaine-guided paravertebral/intraspinal plane nerve blockade for the treatment of acute herpes zoster neuralgia and prevention of postherpetic neuralgia.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076403
Enrollment
Unknown
Registered
2023-10-08
Start date
2023-10-08
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster neuralgia

Interventions

ESPB-LB:The ESPB subjects are positioned in a prone position, and ultrasound guidance is used at the level of the described T10 transverse process. A single injection of ESPB is administered on the af
ESPB-R:The ESPB subjects are positioned in a prone position, and ultrasound guidance is used at the level of the described T10 transverse process. A single injection of ESPB is administered on the aff
PVB-R:The PVB subjects are positioned in a prone position, and ultrasound guidance is used at the level of the described transverse process. A single injection of 0.33% ropivacaine, with a total volum
PVB-LB:Ultrasound guidance is used at the level of the described T10 spinous process. A single injection of 1.33% bupivacaine liposomes, with a total volume of 20 ml, is administered on the affected s

Sponsors

Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.American Society of Anesthesiologists Physical Status Classification (ASA) I-III. 2.Patients diagnosed with postherpetic neuralgia and experiencing pain for less than 30 days. 3.Patients who can cooperate, understand Chinese language, and express their intentions accurately. 4.Willing to participate in the study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.History of allergic reactions to relevant anesthesia drugs. 2.Severe cardiovascular diseases or severe arrhythmias, such as congestive heart failure, complete heart block without a pacemaker, vertebral body fracture, or impaired puncture due to surgery. 3.Infection, damage, or bleeding at the puncture site. 4.Severe peripheral neuropathy or history of mental illness. 5.Severe coagulation dysfunction (INR = 1.4 or platelets = 80,000/uL). 6.Patients deemed unsuitable by the anesthesiologist or surgeon.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;

Secondary

MeasureTime frame
The total amount of analgesic medication used within 72 hours after the puncture.;times of blocks;ID PAIN;HADS;

Countries

China

Contacts

Public ContactWenfei Long

Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

39669618@qq.com+86 185 0209 3523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026